Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial

@article{Wagner2005EffectOG,
  title={Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial},
  author={John E Wagner and John S. Thompson and Shelly L. Carter and Nancy A. Kernan},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={733-741}
}

Figures and Tables from this paper

Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

TLDR
In spite of a significant reduction of acute GVHD, TCD did not reduce the incidence of cGV HD or improve survival in patients who developed cGVHD.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

TLDR
The addition of ATG-F to standard cyclosporine, methotrexate GVHD prophylaxis lowers the incidence and severity of cGVHD, and the risk of receiving IST without raising the relapse rate.

Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease

TLDR
Unrelated-donor marrow transplantation is a potential option for transplant candidates lacking a compatible related donor, and savings on reduced cost for treating acute graft-versus-host disease were likely offset by increase in serious infections in the TCD arm.

T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

  • A. JakubowskiT. Small E. Papadopoulos
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2011

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

  • L. LuznikM. Pasquini M. Perales
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2021
TLDR
CNI-free interventions as performed herein did not result in superior CRFS compared with tacrolimus and methotrexate with BM, and lower rates of moderate and severe cGVHD did not translate into improved survival.

The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial).

  • E. AltmaierM. Ewell R. Gingrich
  • Medicine, Psychology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2006

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

  • M. PasquiniS. Devine R. Soiffer
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
It is suggested that TCD via CD34 selection might lower long-term morbidity as a result of chronic GVHD without negatively impacting relapse rates in patients with acute myeloid leukemia.
...

References

SHOWING 1-10 OF 35 REFERENCES

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.

  • R. SoifferC. Murray R. Gonin
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
It is concluded that selective in vitro T-cell depletion with an anti-T12 monoclonal antibody effectively reduces the incidence of both acute and chronic GVHD after allogeneic BMT without compromising engraftment.

Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation.

TLDR
Bone marrow from 22 histocompatible siblings was depleted of 98% of the lymphocytes using a combination of density flotation centrifugation followed by counterflow elutriation to prevent development of acute graft-v-host disease, provided that immunosuppression is administered after BMT.

Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits.

  • J. WagnerM. Zahurak B. Zehnbauer
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
BMT should be offered early after diagnosis to all patients with CML in CP who have compatible sibling donors regardless of prognostic factors at presentation, and GVHD remains the principal cause of mortality after BMT in patients receiving CsA.

Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose.

TLDR
Transplant in remission with a high dose of marrow cells was associated with the best outcome in both children and adults, and the use of a marrow cell dose above the median translated into less nonleukemic death and better leukemia-free survival in patients transplanted in remission.

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients.

TLDR
It is observed that late infections are more frequent in URD recipients, resulting in substantially higher nonrelapse mortality, and the need for aggressive surveillance and therapy of late infections and perhaps prolonged antibiotic prophylaxis for all URD BMT recipients is suggested.

Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review.

  • D. WeisdorfD. Hurd N. Kernan
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2003

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

TLDR
Bone marrow transplantation done in the chronic phase of chronic myelogenous leukemia offers some patients prolonged leukemia-free survival, and the T-cell-depleted grafts are associated with an increased probability of relapse.

Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation

TLDR
The hypothesis that T cell subsets differentially contribute to alloengraftment and GVHD is supported and the results confirm preclinical studies showing tcrγδ+ T cells promote engraftment.